JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web browser. It makes web pages functional for specific purposes and if disabled for some reason, the content or the functionality of the web page can be limited or unavailable.

Saturday, March 15, 2025

CDC recommends Pfizer, Moderna COVID-19 shots over J&J’s

by

1184 days ago
20211217
FILE - A member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site setup in Philadelphia, on March 26, 2021.  A government advisory panel is meeting Thursday, Dec. 16, to determine if any restrictions are needed to the Johnson & Johnson COVID-19 vaccine because of rare but serious blood clots.  (AP Photo/Matt Rourke, File)

FILE - A member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site setup in Philadelphia, on March 26, 2021. A government advisory panel is meeting Thursday, Dec. 16, to determine if any restrictions are needed to the Johnson & Johnson COVID-19 vaccine because of rare but serious blood clots. (AP Photo/Matt Rourke, File)

By LAU­RAN NEER­GAARD and MIKE STO­BBE | AS­SO­CI­AT­ED PRESS

 

(AP) — Most Amer­i­cans should be giv­en the Pfiz­er or Mod­er­na vac­cines in­stead of the John­son & John­son shot that can cause rare but se­ri­ous blood clots, U.S. health of­fi­cials said Thurs­day.

The strange clot­ting prob­lem has caused nine con­firmed deaths af­ter J&J vac­ci­na­tions — while the Pfiz­er and Mod­er­na vac­cines don’t come with that risk and al­so ap­pear more ef­fec­tive, said ad­vis­ers to the Cen­ters for Dis­ease Con­trol and Pre­ven­tion.

The pan­el rec­om­mend­ed the un­usu­al move of giv­ing pref­er­ence to the Pfiz­er and Mod­er­na vac­cines, and late Thurs­day the CDC’s di­rec­tor, Dr. Rochelle Walen­sky, ac­cept­ed the pan­el’s ad­vice.

Un­til now the U.S. has treat­ed all three COVID-19 vac­cines avail­able to Amer­i­cans as an equal choice, since large stud­ies found they all of­fered strong pro­tec­tion and ear­ly sup­plies were lim­it­ed. J&J’s vac­cine ini­tial­ly was wel­comed as a sin­gle-dose op­tion that could be es­pe­cial­ly im­por­tant for hard-to-reach groups like home­less peo­ple who might not get the need­ed sec­ond dose of the Pfiz­er or Mod­er­na op­tions.

But the CDC’s ad­vis­ers said dur­ing a meet­ing Thurs­day that it was time to rec­og­nize a lot has changed since vac­cines be­gan rolling out a year ago. More than 200 mil­lion Amer­i­cans are con­sid­ered ful­ly vac­ci­nat­ed, in­clud­ing about 16 mil­lion who got the J&J shot.

New da­ta from un­prece­dent­ed safe­ty track­ing of all those vac­ci­na­tions per­suad­ed the pan­el that while the blood clots linked to J&J’s vac­cine re­main very rare, they’re still oc­cur­ring and not just in younger women as orig­i­nal­ly thought.

In a unan­i­mous vote, the ad­vis­ers de­cid­ed the safer Pfiz­er and Mod­er­na vac­cines are pre­ferred. But they said the shot made by J&J’s Janssen di­vi­sion still should be avail­able if some­one re­al­ly wants it — or has a se­vere al­ler­gy to the oth­er op­tions.

“I would not rec­om­mend the Janssen vac­cine to my fam­i­ly mem­bers” but some pa­tients may -- and should be able to -- choose that shot, said CDC ad­vis­er Dr. Beth Bell of the Uni­ver­si­ty of Wash­ing­ton.

The clot­ting prob­lems first came up last spring, with the J&J shot in the U.S. and with a sim­i­lar vac­cine made by As­traZeneca that is used in oth­er coun­tries. Even­tu­al­ly U.S. reg­u­la­tors de­cid­ed the ben­e­fits of J&J’s one-and-done vac­cine out­weighed what was con­sid­ered a very rare risk — as long as re­cip­i­ents were warned.

Eu­ro­pean reg­u­la­tors like­wise con­tin­ued to rec­om­mend As­traZeneca’s two-dose vac­cine al­though, be­cause ear­ly re­ports were most­ly in younger women, some coun­tries is­sued age re­stric­tions.

COVID-19 caus­es dead­ly blood clots, too. But the vac­cine-linked kind is dif­fer­ent, be­lieved to form be­cause of a rogue im­mune re­ac­tion to the J&J and As­traZeneca vac­cines be­cause of how they’re made. It forms in un­usu­al places, such as veins that drain blood from the brain, and in pa­tients who al­so de­vel­op ab­nor­mal­ly low lev­els of the platelets that form clots. Symp­toms of the un­usu­al clots, dubbed “throm­bo­sis with throm­bo­cy­tope­nia syn­drome,” in­clude se­vere headaches a week or two af­ter the J&J vac­ci­na­tion — not right away — as well as ab­dom­i­nal pain and nau­sea.

While it’s still very rare, the Food and Drug Ad­min­is­tra­tion told health care providers this week that more cas­es have oc­curred af­ter J&J vac­ci­na­tions since the spring. They oc­cur most in women ages 30 to 49 -- about once for every 100,000 dos­es ad­min­is­tered, the FDA said.

Over­all, the gov­ern­ment has con­firmed 54 clot cas­es— 37 in women and 17 in men, and nine deaths that in­clud­ed two men, the CDC’s Dr. Isaac See said Thurs­day. He said two ad­di­tion­al deaths are sus­pect­ed.

The CDC de­cides how vac­cines should be used in the U.S., and its ad­vis­ers called the con­tin­u­ing deaths trou­bling. In com­par­ing the pros and cons of all the vac­cines, the pan­elists agreed that side ef­fects from the Pfiz­er and Mod­er­na vac­cines weren’t as se­ri­ous — and that sup­plies now are plen­ti­ful.

Nor is J&J still con­sid­ered a one-and-done vac­cine, sev­er­al ad­vis­ers not­ed. The sin­gle-dose op­tion didn’t prove quite as pro­tec­tive as two dos­es of the Pfiz­er and Mod­er­na vac­cines. Plus, with ex­tra-con­ta­gious virus mu­tants now spread­ing, boost­er dos­es now are rec­om­mend­ed.

For J&J re­cip­i­ents, a boost­er is rec­om­mend­ed at least two months af­ter vac­ci­na­tion. U.S. health of­fi­cials had pre­vi­ous­ly okayed mix­ing vac­cines for boost­er shots.

Sev­er­al coun­tries, in­clud­ing Cana­da, al­ready have poli­cies that give pref­er­ence to the Pfiz­er and Mod­er­na vac­cines. But J&J told the com­mit­tee its vac­cine still of­fers strong pro­tec­tion and is a crit­i­cal op­tion es­pe­cial­ly in parts of the world with­out plen­ti­ful vac­cine sup­plies or for peo­ple who don’t want a two-dose shot.

While blood clots are rare, “un­for­tu­nate­ly cas­es of COVID-19 are not,” J&J’s Dr. Pen­ny Heaton said.

The U.S. is for­tu­nate in its vac­cine avail­abil­i­ty and Thurs­day’s ac­tion shouldn’t dis­cour­age use of J&J’s vac­cine in places around the world where it’s need­ed, said CDC ad­vis­er Dr. Matthew Da­ley of Kaiser Per­ma­nente Col­orado.

The FDA al­so warned this week that an­oth­er dose of the J&J vac­cine shouldn’t be giv­en to any­one who de­vel­oped a clot fol­low­ing ei­ther a J&J or As­traZeneca shot.

The com­mit­tee al­so heard some of the first da­ta on re­port­ed side ef­fects of Pfiz­er vac­ci­na­tions in younger chil­dren. Ear­ly last month, the CDC rec­om­mend­ed a two-dose se­ries for that age group, and more than 7 mil­lion dos­es have been giv­en so far. But few prob­lems have been re­port­ed. Of the 80 re­port­ed cas­es of se­ri­ous side ef­fects, about 10 in­volved a form of in­flam­ma­tion that has been seen in male teens and young adults.

COVID-19HealthUnited States


Related articles

Sponsored

Weather

PORT OF SPAIN WEATHER

Sponsored